MIAMI--(BUSINESS WIRE)--Sep 6, 2018--Gibson Oncology, LLC (“Gibson”), a privately held clinical stage company, acquired three (3) clinical non-camptothecin Topoisomerase I drugs from Linus Oncology. These novel anti-cancer drugs have been tested in over 70 patients by the National Cancer Institute (NCI) and have been shown to be both safe and effective in phase I clinical trials. There are multiple United States and international patents on these agents.

The compounds acquired are indenoisoquinolines (“indenos”), a novel class of drugs which were invented and developed by Purdue University and the NCI to minimize the diarrhea and neutropenia associated with the administration of traditional camptothecin agents such as irinotecan and topotecan. The multiple phase I trials have shown effectiveness in end-stage cancer patients with solid tumors who had failed administration of up to nine (9) drugs given previously. Simultaneously, these new drugs dramatically reduce the incidence of grade 3 and 4 neutropenia and diarrhea.

In addition, Gibson strengthened its Indeno product platform through obtaining an exclusive, worldwide development and commercialization license from Purdue University for the recently discovered pro-drugs for this novel class of compounds.

With pre-clinical studies already performed which demonstrate both the effectiveness of indenos after the development of irinotecan resistance as well as synergy between PARP inhibitors and the indenos, Gibson intends to approach the FDA about phase II studies. Several academic organizations, both in the United States and in Europe, have approached Gibson about helping conduct these studies.

“We are excited to advance these novel, potent, and well-tolerated small molecule topoisomerase I inhibitor drugs in advanced stage and/or resistant cancers as a single agent or in combination with immune-oncology and targeted therapies for improved patient outcomes,” stated Randall Riggs, CEO of Gibson Oncology, LLC.

About Gibson

Gibson is a private oncology drug development company dedicated to bringing its novel, cost-effective, and very well-tolerated Indeno anti-cancer treatments to market. Gibson intends to develop these novel anti-cancer drugs in advanced-stage cancer patients as single agent and in combination treatments with both immunotherapy and targeted therapies.

View source version on

CONTACT: Gibson Oncology, LLC

Elizabeth L Rogers, MD



SOURCE: Gibson Oncology, LLC

Copyright Business Wire 2018.

PUB: 09/06/2018 07:25 AM/DISC: 09/06/2018 07:25 AM